Alexion Pharmaceuticals (ALXN) 144.46 $ALXN
New Data Presented at WORLDSymposium(TM) 2016 Show Substantial Survival Benefit Beyond 2 Years of Age in Infants with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma(TM) (sebelipase alfa)
Business Wire - Thu Mar 03, 4:15PM CST
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that researchers presented new two-year data from an ongoing, open-label Phase 2/3 trial of Kanuma(TM) (sebelipase alfa) in infants with lysosomal acid lipase deficiency (LAL-D), a genetic and progressive ultra-rare metabolic disease. Data from this study demonstrated a substantial survival benefit (56 percent, or 5 out of 9) to beyond 2 years of age for patients with rapidly progressive LAL-D during infancy who were treated with Kanuma, with the longest-treated patient surviving to over 5 years of age.(1) Patients also had improvements in a number of key parameters, including weight gain, important markers of liver disease, gastrointestinal symptoms, anemia, and hepatosplenomegaly (enlargement of both the liver and spleen), and 4 out of 5 patients demonstrated normal development.(1) These data were reported in an oral presentation at the 12th Annual WORLDSymposium(TM) in San Diego. Additionally, researchers reported favorable findings from an analysis of safety data from three ongoing, long-term trials evaluating Kanuma in children and adults with LAL-D.(2)
ALXN: 144.46 (-1.39)
Ensemble Therapeutics Achieves Milestone
Business Wire - Thu Mar 03, 11:10AM CST
Ensemble Therapeutics, a biotechnology company focused on discovering and developing breakthrough small molecule therapies for cancer and other serious diseases, today announced that it has achieved an early-stage research milestone in its drug discovery collaboration with Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), triggering a milestone payment to Ensemble. Under the terms of the agreement, Ensemble is applying its drug discovery platform against several Alexion targets to discover new small molecule clinical candidates. Alexion will have exclusive worldwide rights to develop and commercialize candidates arising from the collaboration.
ALXN: 144.46 (-1.39)
These 3 Biotechs Are Growing Fast -- Which Is the Best Buy Today?
Brian Feroldi, The Motley Fool - Motley Fool - Thu Mar 03, 9:45AM CST
Image source: Juliacdrd via pixabay. We are only a quarter of the way through 2016, but it's already been a year that most biotechnology investors would rather forget. The iShares Nasdaq Biotechnology ETF , an exchange-traded fund that owns a...
VRTX: 88.36 (-1.09), ALXN: 144.46 (-1.39), IBB: 263.13 (-1.11), REGN: 403.82 (+1.88)
Biotech Stock Roundup: Gilead HIV Drug Approved, Baxalta in Immuno-Oncology Deal
Arpita Dutt - Zacks Investment Research - Wed Mar 02, 1:35PM CST
Major biotech stocks were up last week while companies like Gilead (GILD) provided positive regulatory updates.
CARA: 5.39 (-0.25), VRTX: 88.36 (-1.09), GILD: 87.21 (-0.62), ALXN: 144.46 (-1.39), PTCT: 6.06 (-0.04), AMGN: 145.98 (+0.14), BXLT: 39.47 (+0.17)
2 Reasons Alexion Pharmaceuticals' Stock Could Rise
Brian Feroldi, The Motley Fool - Motley Fool - Fri Feb 19, 12:43PM CST
Image source: TBIT via pixabay. Alexion Pharmaceuticals ' stock is off to a rough start for the year. The company's shares have traded right in lockstep with the biotech stock in general -- as measured by the iShares Nasdaq Biotechnology ETF --...
ALXN: 144.46 (-1.39)
Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma
Arpita Dutt - Zacks Investment Research - Wed Feb 10, 10:02AM CST
Disappointing pipeline and regulatory updates from companies like CTI BioPharma (CTIC) and Sarepta (SRPT) and earnings misses from Alexion and Regeneron were the highlights this week.
BCRX: 2.58 (-0.03), VRTX: 88.36 (-1.09), GILD: 87.21 (-0.62), SRPT: 14.29 (+0.02), ALXN: 144.46 (-1.39), CTIC: 0.59 (-0.01), REGN: 403.82 (+1.88)
Alexion Pharmaceuticals Falls 1.93% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Feb 09, 6:35PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $134.00 to a high of $142.07. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $136.44 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 144.46 (-1.39)
Biotech ETFs Slide as Stocks Report Mixed Q4 Results
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 12:48PM CST
Thanks to mixed results, the biotech sector has failed to gain investor confidence so far in the fourth quarter.
PBE: 38.64 (-0.12), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62), FBT: 88.37 (+0.55), ALXN: 144.46 (-1.39), BBH: 103.52 (-0.23), IBB: 263.13 (-1.11), AMGN: 145.98 (+0.14), CELG: 102.51 (-0.22)
Alexion Pharmaceuticals Down 20.4% Since SmarTrend Downtrend Call (ALXN)
Comtex SmarTrend(R) - Tue Feb 09, 9:58AM CST
SmarTrend identified a Downtrend for Alexion Pharmaceuticals (NASDAQ:ALXN) on January 8th, 2016 at $171.39. In approximately 1 month, Alexion Pharmaceuticals has returned 20.42% as of today's recent price of $136.38.
ALXN: 144.46 (-1.39)
Alexion Pharmaceuticals' Big Top Foreshadows Big Drop
at The Street - Mon Feb 08, 12:32PM CST
The next potential support levels are the $120 and $100 areas from 2013.
ALXN: 144.46 (-1.39)
The Key Takeaways From Alexion Pharmaceuticals Inc.'s Earnings Release
Brian Feroldi, The Motley Fool - Motley Fool - Fri Feb 05, 4:57PM CST
Image by TBIT via Pixabay. Biotech heavyweight Alexion Pharmaceuticals released its fourth-quarter 2015 earnings results before the opening bell Wednesday. Like many other biotechs, Alexion's shares have taken a beating recently, as they have...
ALXN: 144.46 (-1.39), IBB: 263.13 (-1.11)
Alexion to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Business Wire - Thu Feb 04, 9:00AM CST
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 at 1:50 p.m., Eastern Time.
ALXN: 144.46 (-1.39)
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.3%
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 7:15AM CST
Alexion Pharmaceuticals, Inc. (ALXN) shares rose over 6% in the last trading session.
ALXN: 144.46 (-1.39), ANIK: 45.07 (-0.43)
'Mad Money' Lightning Round: Take Celgene Over Alexion Pharmaceuticals
at The Street - Thu Feb 04, 5:00AM CST
Cramer prefers McCormick to McKesson and is staying away from Ferrellgas Partners and BP.
70.62 (+0.63), MCK: 162.77 (+0.07), MKC: 93.93 (+0.18), DUK: 75.17 (+0.84), GNRC: 34.91 (-0.43), ALXN: 144.46 (-1.39), SYY: 45.02 (+0.02), BP: 31.15 (+0.28), FGP: 18.45 (-0.10), CELG: 102.51 (-0.22)
Alexion Pharma (ALXN) Earnings Report: Q4 2015 Conference Call Transcript
at The Street - Wed Feb 03, 8:38PM CST
The following Alexion Pharma (ALXN) conference call took place on February 3, 2016, 10:00 AM ET. This is a transcript of that earnings call:
ALXN: 144.46 (-1.39)
Jim Cramer's 'Mad Money' Recap: Investors Dare to Hope as Oil Gushes
at The Street - Wed Feb 03, 7:21PM CST
Cramer says things are looking a little less crazy than they were Tuesday.
FIT: 12.86 (+0.39), 70.62 (+0.63), MMM: 160.07 (+0.69), MCK: 162.77 (+0.07), ETN: 57.95 (+0.12), CLX: 125.61 (+0.02), MKC: 93.93 (+0.18), DUK: 75.17 (+0.84), SYY: 45.02 (+0.02), PYPL: 39.04 (+0.02), INTC: 30.63 (+0.05), CELG: 102.51 (-0.22), GNRC: 34.91 (-0.43), ALXN: 144.46 (-1.39), BP: 31.15 (+0.28), FGP: 18.45 (-0.10), ACN: 103.18 (+0.38), CRM: 71.06 (+0.26)
Alexion Misses on Earnings and Revenues in Q4, Gives View
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 9:50AM CST
Alexion Pharmaceuticals (ALXN) reported fourth-quarter 2015 earnings (including stock-based compensation expense) of 84 cents.
GILD: 87.21 (-0.62), ALXN: 144.46 (-1.39), ANIK: 45.07 (-0.43), CELG: 102.51 (-0.22)
New Data Presented at WORLDSymposium(TM) 2016 Show Substantial Survival Benefit Beyond 2 Years of Age in Infants with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma(TM) (sebelipase alfa)
Business Wire - Thu Mar 03, 4:15PM CST
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that researchers presented new two-year data from an ongoing, open-label Phase 2/3 trial of Kanuma(TM) (sebelipase alfa) in infants with lysosomal acid lipase deficiency (LAL-D), a genetic and progressive ultra-rare metabolic disease. Data from this study demonstrated a substantial survival benefit (56 percent, or 5 out of 9) to beyond 2 years of age for patients with rapidly progressive LAL-D during infancy who were treated with Kanuma, with the longest-treated patient surviving to over 5 years of age.(1) Patients also had improvements in a number of key parameters, including weight gain, important markers of liver disease, gastrointestinal symptoms, anemia, and hepatosplenomegaly (enlargement of both the liver and spleen), and 4 out of 5 patients demonstrated normal development.(1) These data were reported in an oral presentation at the 12th Annual WORLDSymposium(TM) in San Diego. Additionally, researchers reported favorable findings from an analysis of safety data from three ongoing, long-term trials evaluating Kanuma in children and adults with LAL-D.(2)
ALXN: 144.46 (-1.39)
Ensemble Therapeutics Achieves Milestone
Business Wire - Thu Mar 03, 11:10AM CST
Ensemble Therapeutics, a biotechnology company focused on discovering and developing breakthrough small molecule therapies for cancer and other serious diseases, today announced that it has achieved an early-stage research milestone in its drug discovery collaboration with Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), triggering a milestone payment to Ensemble. Under the terms of the agreement, Ensemble is applying its drug discovery platform against several Alexion targets to discover new small molecule clinical candidates. Alexion will have exclusive worldwide rights to develop and commercialize candidates arising from the collaboration.
ALXN: 144.46 (-1.39)
These 3 Biotechs Are Growing Fast -- Which Is the Best Buy Today?
Brian Feroldi, The Motley Fool - Motley Fool - Thu Mar 03, 9:45AM CST
Image source: Juliacdrd via pixabay. We are only a quarter of the way through 2016, but it's already been a year that most biotechnology investors would rather forget. The iShares Nasdaq Biotechnology ETF , an exchange-traded fund that owns a...
VRTX: 88.36 (-1.09), ALXN: 144.46 (-1.39), IBB: 263.13 (-1.11), REGN: 403.82 (+1.88)
Biotech Stock Roundup: Gilead HIV Drug Approved, Baxalta in Immuno-Oncology Deal
Arpita Dutt - Zacks Investment Research - Wed Mar 02, 1:35PM CST
Major biotech stocks were up last week while companies like Gilead (GILD) provided positive regulatory updates.
CARA: 5.39 (-0.25), VRTX: 88.36 (-1.09), GILD: 87.21 (-0.62), ALXN: 144.46 (-1.39), PTCT: 6.06 (-0.04), AMGN: 145.98 (+0.14), BXLT: 39.47 (+0.17)
2 Reasons Alexion Pharmaceuticals' Stock Could Rise
Brian Feroldi, The Motley Fool - Motley Fool - Fri Feb 19, 12:43PM CST
Image source: TBIT via pixabay. Alexion Pharmaceuticals ' stock is off to a rough start for the year. The company's shares have traded right in lockstep with the biotech stock in general -- as measured by the iShares Nasdaq Biotechnology ETF --...
ALXN: 144.46 (-1.39)
Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma
Arpita Dutt - Zacks Investment Research - Wed Feb 10, 10:02AM CST
Disappointing pipeline and regulatory updates from companies like CTI BioPharma (CTIC) and Sarepta (SRPT) and earnings misses from Alexion and Regeneron were the highlights this week.
BCRX: 2.58 (-0.03), VRTX: 88.36 (-1.09), GILD: 87.21 (-0.62), SRPT: 14.29 (+0.02), ALXN: 144.46 (-1.39), CTIC: 0.59 (-0.01), REGN: 403.82 (+1.88)
Alexion Pharmaceuticals Falls 1.93% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Feb 09, 6:35PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $134.00 to a high of $142.07. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $136.44 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 144.46 (-1.39)
Biotech ETFs Slide as Stocks Report Mixed Q4 Results
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 12:48PM CST
Thanks to mixed results, the biotech sector has failed to gain investor confidence so far in the fourth quarter.
PBE: 38.64 (-0.12), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62), FBT: 88.37 (+0.55), ALXN: 144.46 (-1.39), BBH: 103.52 (-0.23), IBB: 263.13 (-1.11), AMGN: 145.98 (+0.14), CELG: 102.51 (-0.22)
Alexion Pharmaceuticals Down 20.4% Since SmarTrend Downtrend Call (ALXN)
Comtex SmarTrend(R) - Tue Feb 09, 9:58AM CST
SmarTrend identified a Downtrend for Alexion Pharmaceuticals (NASDAQ:ALXN) on January 8th, 2016 at $171.39. In approximately 1 month, Alexion Pharmaceuticals has returned 20.42% as of today's recent price of $136.38.
ALXN: 144.46 (-1.39)
Alexion Pharmaceuticals' Big Top Foreshadows Big Drop
at The Street - Mon Feb 08, 12:32PM CST
The next potential support levels are the $120 and $100 areas from 2013.
ALXN: 144.46 (-1.39)
The Key Takeaways From Alexion Pharmaceuticals Inc.'s Earnings Release
Brian Feroldi, The Motley Fool - Motley Fool - Fri Feb 05, 4:57PM CST
Image by TBIT via Pixabay. Biotech heavyweight Alexion Pharmaceuticals released its fourth-quarter 2015 earnings results before the opening bell Wednesday. Like many other biotechs, Alexion's shares have taken a beating recently, as they have...
ALXN: 144.46 (-1.39), IBB: 263.13 (-1.11)
Alexion to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Business Wire - Thu Feb 04, 9:00AM CST
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 at 1:50 p.m., Eastern Time.
ALXN: 144.46 (-1.39)
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.3%
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 7:15AM CST
Alexion Pharmaceuticals, Inc. (ALXN) shares rose over 6% in the last trading session.
ALXN: 144.46 (-1.39), ANIK: 45.07 (-0.43)
'Mad Money' Lightning Round: Take Celgene Over Alexion Pharmaceuticals
at The Street - Thu Feb 04, 5:00AM CST
Cramer prefers McCormick to McKesson and is staying away from Ferrellgas Partners and BP.
70.62 (+0.63), MCK: 162.77 (+0.07), MKC: 93.93 (+0.18), DUK: 75.17 (+0.84), GNRC: 34.91 (-0.43), ALXN: 144.46 (-1.39), SYY: 45.02 (+0.02), BP: 31.15 (+0.28), FGP: 18.45 (-0.10), CELG: 102.51 (-0.22) Alexion Pharma (ALXN) Earnings Report: Q4 2015 Conference Call Transcript
at The Street - Wed Feb 03, 8:38PM CST
The following Alexion Pharma (ALXN) conference call took place on February 3, 2016, 10:00 AM ET. This is a transcript of that earnings call:
ALXN: 144.46 (-1.39)
Jim Cramer's 'Mad Money' Recap: Investors Dare to Hope as Oil Gushes
at The Street - Wed Feb 03, 7:21PM CST
Cramer says things are looking a little less crazy than they were Tuesday.
FIT: 12.86 (+0.39),
70.62 (+0.63), MMM: 160.07 (+0.69), MCK: 162.77 (+0.07), ETN: 57.95 (+0.12), CLX: 125.61 (+0.02), MKC: 93.93 (+0.18), DUK: 75.17 (+0.84), SYY: 45.02 (+0.02), PYPL: 39.04 (+0.02), INTC: 30.63 (+0.05), CELG: 102.51 (-0.22), GNRC: 34.91 (-0.43), ALXN: 144.46 (-1.39), BP: 31.15 (+0.28), FGP: 18.45 (-0.10), ACN: 103.18 (+0.38), CRM: 71.06 (+0.26) Alexion Misses on Earnings and Revenues in Q4, Gives View
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 9:50AM CST
Alexion Pharmaceuticals (ALXN) reported fourth-quarter 2015 earnings (including stock-based compensation expense) of 84 cents.
GILD: 87.21 (-0.62), ALXN: 144.46 (-1.39), ANIK: 45.07 (-0.43), CELG: 102.51 (-0.22)
